Literature DB >> 12225359

Immunological weapons against acute myeloid leukaemia.

Joanna Galea-Lauri1.   

Abstract

A better understanding of the biology of malignant cells and of the host immune system together with dramatic advances in technology have led to the design of innovative immune-mediated approaches to control neoplastic clones, including various haematological malignancies. One of the major problems with conventional cancer therapies is their inability to eradicate residual cancer cells that are resistant to therapy, hence immune intervention might improve the clinical outcome of patients. This mini-review will focus mainly on immunological approaches to the therapy of acute myeloid leukaemia (AML), a subset of a much larger family of leukaemias. Immune-mediated approaches ranging from allogeneic lymphocyte transplants to cytokine therapy, immune-gene therapy and vaccination by dendritic-cell-based vaccines will be discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12225359      PMCID: PMC1782763          DOI: 10.1046/j.1365-2567.2002.01497.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  85 in total

1.  Natural adjuvants: endogenous activators of dendritic cells.

Authors:  S Gallucci; M Lolkema; P Matzinger
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

Review 2.  Interleukin 2 and its receptors: recent advances and new immunological functions.

Authors:  J Thèze; P M Alzari; J Bertoglio
Journal:  Immunol Today       Date:  1996-10

3.  Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD34+ hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients.

Authors:  S Fujii; K Fujimoto; K Shimizu; T Ezaki; F Kawano; K Takatsuki; M Kawakita; K Matsuno
Journal:  Cancer Res       Date:  1999-05-01       Impact factor: 12.701

4.  Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.

Authors:  K Dunussi-Joannopoulos; G Dranoff; H J Weinstein; J L Ferrara; B E Bierer; J M Croop
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Autoimmune disease induced by dendritic cell immunization against leukemia.

Authors:  M A Roskrow; D Dilloo; N Suzuki; W Zhong; C M Rooney; M K Brenner
Journal:  Leuk Res       Date:  1999-06       Impact factor: 3.156

Review 6.  The potential for antitumor vaccination in acute myelogenous leukemia.

Authors:  R J Arceci
Journal:  J Mol Med (Berl)       Date:  1998-02       Impact factor: 4.599

7.  The role of T cell costimulation by CD80 in the initiation and maintenance of the immune response to human leukemia.

Authors:  K Matsumoto; C Anasetti
Journal:  Leuk Lymphoma       Date:  1999-11

8.  CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens.

Authors:  T Mutis; E Schrama; C J Melief; E Goulmy
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

9.  Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression.

Authors:  A Cignetti; A Guarini; A Carbone; M Forni; K Cronin; G Forni; B Gansbacher; R Foa
Journal:  J Natl Cancer Inst       Date:  1994-05-18       Impact factor: 13.506

10.  Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

Authors:  J A Thompson; D J Peace; J P Klarnet; D E Kern; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

View more
  4 in total

1.  Conjugation of lentivirus to paramagnetic particles via nonviral proteins allows efficient concentration and infection of primary acute myeloid leukemia cells.

Authors:  Lucas Chan; Darren Nesbeth; Taylor Mackey; Joanna Galea-Lauri; Joop Gäken; Francisco Martin; Mary Collins; Ghulam Mufti; Farzin Farzaneh; David Darling
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

2.  In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC.

Authors:  Maryam Nourizadeh; Farimah Masoumi; Ali Memarian; Kamran Alimoghaddam; Seyed Mohammad Moazzeni; Marjan Yaghmaie; Jamshid Hadjati
Journal:  Target Oncol       Date:  2013-07-14       Impact factor: 4.493

3.  Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; James A Thompson; Suzanne Ostrand-Rosenberg; Theresia M Westers; Yuri Souwer; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Haematologica       Date:  2009-11-10       Impact factor: 9.941

4.  Optimization and limitation of calcium ionophore to generate DCs from acute myeloid leukemic cells.

Authors:  Thanh-Nhan Nguyen Pham; Bo-Hwa Choi; Hyun-Kyu Kang; Chun-Chi Jin; Nguyen Hoang Tuyet Minh; Sang-Ki Kim; Jong-Hee Nam; Deok-Hwan Yang; Yeo-Kyeoung Kim; Hyeoung-Joon Kim; Ik-Joo Chung; Je-Jung Lee
Journal:  Cancer Res Treat       Date:  2007-12-31       Impact factor: 4.679

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.